Welcome to the p53Lab

ImageThe p53 lab is focusing on the development of new therapies, new diagnostics and new discoveries in the p53 pathway. 11 Million people living with cancer have specific mutations in the p53 gene leading to the production of a faulty p53 protein. This is half the cases of human cancer. In those that have an apparently normal p53 gene we believe that there are faults in the p53 pathway. We are using a variety of approaches to translate this extraordinary finding into clinical benefit. We work closely with many other groups both in Singapore and in the rest of the world to achieve this. We are using biochemical, biophysical, cell biological and genetic approaches in our work and offer an outstanding international training environment



Upcoming Conferences (2020)

Current Publications

Diller DJ, Swanson J, Bayden AS, Brown CJ, Thean D, Lane DP, Partridge AW, Sawyer TK, Audie J (2019). Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides. Molecules. Dec 14; 24(24). doi: 10.3390/molecules24244586  

Gago FJF, Koh LQ, Lane DP (2019). New Functionalized Resins for the Synthesis of Peptide Alcohols. 14 Oct. Chemistry - a European Journal.

Frosi Y, Inoue K, Ramlan SR, Lane DP, Watanabe T and Brown CJ (2019). Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci. Scientific Reports volume 9, Article number: 17933

Pradhan MR, Siau JW, Kannan S, Nguyen MN, Ouaray Z, Kwoh CK, Lane DP, Ghadessy F, Verma CS (2019). Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket. Nucleic Acids Research, 47(4), 1637–1652.

Xue Y, Barker N, Hoon S, He P, Thakur T, Abdeen SR, Maruthappan P, Ghadessy FJ, Lane DP (2019). Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of both Normal and Tumor Tissues In Vivo. Cancer Res, 79(14), 3595-3607.

Partridge AW, Kaan HYK, Juang YC, Sadruddin A, Lim S, Brown CJ, Ng S, Thean D, Ferrer F, Johannes C, Yuen TY, Kannan S, Aronica P, Tan YS, Pradhan MR, Verma CS, Hochman J, Chen S, Wan H, Ha S, Sherborne B2, Lane DP, Sawyer TK (2019). Incorporation of putative helix-breaking amino acids in the design of novel stapled peptides: Exploring biophysical and cellular permeability properties. Molecules, 24(12).

Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP (2019). Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase . Oncogene. doi: 10.1038/s41388-019-0946-8. [Epub ahead of print].

Sana B, Chee SMQ, Wongsantichon J, Raghavan S, Robinson RC, Ghadessy FJ (2019). Development and structural characterization of an engineered multi-copper oxidase reporter of protein-protein interactions. J Biol Chem, 294(17), 7002-7012. doi: 10.1074/jbc.RA118.007141. Epub 2019 Feb 15.

Yuen TY, Brown CJ, Xue Y, Tan YS, Ferrer Gago FJ, Lee XE, Neo JY, Thean D, Kaan HYK, Partridge AW, Verma CS, Lane DP, Johannes CW (2019). Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles. Chem Sci, 10(26).

Lama D, Liberatore AM, Frosi Y, Nakhle J, Tsomaia N, Bashir T, Lane DP, Brown CJ, Verma CS, Auvin, S. (2019). Structural insights reveal arecognition feature for tailoring hydrocarbon stapled-peptides againstthe eukaryotic translation initiation factor 4E protein. S. Chem Sci., 10(8), 2489-2500.

Lundgren Mortensen AC, Spiegelberg D, Brown CJ, Lane DP, Nestor M (2019). The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells. Front. Oncol., 19 September 2019. doi.org: 10.3389/fonc.2019.0092